This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Alibaba, Airbnb & Royal Caribbean Cruises
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Airbnb, Inc. (ABNB) and Royal Caribbean Cruises Ltd. (RCL), as well a micro-cap stock DallasNews Corporation (DALN).
Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth
by Zacks Equity Research
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Edwards Lifesciences Stock Stay in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
DexCom (DXCM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Is the Options Market Predicting a Spike in Edwards (EW) Stock?
by Zacks Equity Research
Investors need to pay close attention to Edwards (EW) stock based on the movements in the options market lately.
Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' robust potential in Structural heart and long-term strategy instill optimism.
Globus Medical (GMED) Up 2.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Evidence on SAPIEN 3 Ultra RESILIA Valve Set to Boost EW Stock
by Zacks Equity Research
Edwards' SAPIEN 3 Ultra RESILIA Valve continues to deliver excellent outcomes for patients in real-world data.
International Markets and Edwards Lifesciences (EW): A Deep Dive for Investors
by Zacks Equity Research
Explore Edwards Lifesciences' (EW) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
Edwards Lifesciences reports strong contributions from all of the product groups - TAVR, TTMT and surgical structural heart - in the third quarter of 2024.
Compared to Estimates, Edwards Lifesciences (EW) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
TFX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Earnings Preview: DexCom (DXCM) Q3 Earnings Expected to Decline
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
EW is likely to have witnessed continued growth in TAVR procedures across the United States and worldwide in the third quarter.
TFX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Is it the Right Time to Hold EW Stock in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.
TFX vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Why Is Globus Medical (GMED) Down 0.2% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BD Stock Falls After Acquisition of Edwards' Critical Care Group
by Zacks Equity Research
BDX expands its smart care portfolio by acquiring Edwards Lifesciences' Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven health solutions.
EW Stock Dips Following the Divestiture of Critical Care Wing
by Zacks Equity Research
Edwards completes the sale of its Critical Care operations and announces a $1 billion share repurchase program.
EW Stock to Benefit From Favorable RHEIA Trial Data on TAVI
by Zacks Equity Research
Edwards' first all-female TAVI Trial demonstrates favorable outcomes for women receiving Edwards valves.
Why Is Waters (WAT) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.